Patents Expiring in August 2033
✉ Email this page to a colleague
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ardelyx Inc | IBSRELA | tenapanor hydrochloride | TABLET;ORAL | 211801-001 | Sep 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | |||
Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-001 | Oct 17, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | |||
Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-002 | Oct 17, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | |||
Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-003 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | |||
Apellis Pharms | SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171-001 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |